3 citations
,
November 2019 in “Journal of dermatology” Itraconazole effectively treated a woman's painful skin condition and hair loss.
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
16 citations
,
December 2001 in “The Journal of Dermatology” A woman recovered from hair loss and skin eruptions after stopping a tuberculosis drug and using steroids.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” 4 citations
,
September 2024 in “BMC Cancer”
1 citations
,
April 2020 in “Clinical, Cosmetic and Investigational Dermatology” Acyclovir cream may slow down hair growth, suggesting it could be a new treatment for excessive hairiness.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
September 2018 in “Practical diabetes” Sodium valproate is not recommended as a first-line treatment for neuropathy but may be used in resistant cases.
2 citations
,
January 2017 in “Düşünen Adam” Agomelatine might help stop hair loss caused by valproate.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
3 citations
,
January 1990 in “Cancer chemotherapy and pharmacology” Topical thiols may prevent hair loss caused by certain chemotherapy drugs.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
11 citations
,
July 2020 in “Scientific Reports” Statins may be linked to reproductive organ conditions, and their risks should be monitored.
6 citations
,
March 2014 in “Annals of Pharmacotherapy” A woman's hair loss was probably caused by the antifungal drug anidulafungin.
April 2023 in “Dermatology practical & conceptual” Lenalidomide helps hair follicle stem cells turn into melanocytes, which may improve repigmentation in vitiligo.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
November 2024 in “Rheumatology Advances in Practice” Monitor for early signs of azathioprine toxicity and check blood counts regularly.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
May 2024 in “Reactions weekly”
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
16 citations
,
August 2002 in “Journal of Interferon and Cytokine Research” A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.
March 2026 in “Journal of Translational Autoimmunity” This study investigates the mechanisms by which ruxolitinib, a JAK inhibitor, reverses alopecia areata (AA) in a C3H/HeJ mouse model. Over 98 days, ruxolitinib treatment led to significant hair regrowth by day 85, reduced inflammatory cytokines, decreased T-cell infiltration, and lowered STAT phosphorylation. It also attenuated local oxidative stress and keratinocyte apoptosis without affecting autophagy or systemic oxidative markers. The study concludes that ruxolitinib's efficacy in treating AA is due to a triple mechanism: inhibition of the JAK-STAT pathway, reduction of local oxidative stress and apoptosis, and disruption of the inflammatory cycle, supporting the potential for targeted topical therapies.
Levetiracetam and valproate sodium both reduce seizures when added to lamotrigine, but levetiracetam has fewer side effects.
14 citations
,
August 2019 in “Dermatologic Therapy” January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.